Fly News Breaks for February 3, 2020
Feb 3, 2020 | 07:13 EDT
SunTrust analyst Robyn Karnauskas lowered her price target on Amgen to $254 after its Q4 results and outlook by the management anticipating pricing and competitive headwinds in 2020. The analyst still keeps her Buy rating however and sees the company as a "leader in commercializing assets" with a history of enduring pricing pressure by growing through volume. Karnauskas also points to two positive phase 3 catalysts for Amgen in 2020, which include omemcativ in Q4 and tezepelumab in asthma by year-end.
News For AMGN From the Last 2 Days
There are no results for your query AMGN